Pneumovax™ 23

BIOLOGICAL4 trials

Sponsors

Merck Sharp & Dohme LLC, GlaxoSmithKline

Conditions

InfluenzaPneumococcal DiseasePneumococcal InfectionPneumococcal Infections

Phase 3

A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)

CompletedNCT01734239

Merck Sharp & Dohme LLCPneumococcal Disease

Start: 2013-06-03End: 2013-10-22Updated: 2018-10-30

Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older

CompletedNCT02218697

GlaxoSmithKlineInfluenza

Start: 2014-10-01End: 2015-05-04Updated: 2018-04-03

Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)

CompletedNCT02225587

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2014-08-28End: 2015-07-06Updated: 2021-11-02

Phase 4

Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)

CompletedNCT02260882

Merck Sharp & Dohme LLCPneumococcal Infection

Start: 2014-10-31End: 2015-04-09Updated: 2018-10-30

Related Papers

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Human Vaccines & Immunotherapeutics2021-05-2115 citations

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in adults ≥50 years of age: Results from a phase III, randomized, non-inferiority trial

Vaccine2017-10-1132 citations

Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses

Vaccine2016-06-1218 citations

Safety and immunogenicity of a single dose 23-valent pneumococcal polysaccharide vaccine in Russian subjects.

2016-05-058 citations